Drugs in R&D publishes original research and reviews from all phases of drug development and on clinical use of drugs following approval.
The journal was re-launched in 2010 as the first Open Access journal from Adis, making all content from 2010 onwards freely available online. Pre-2010 content is not available as Open Access.
Drugs in R&D offers a range of additional enhanced features designed to increase the visibility, readership and educational value of the journal’s content. Each article is accompanied by a Key Points summary, giving a time-efficient overview of the content to a wide readership. Articles may be accompanied by plain language summaries to assist readers in understanding important medical advances. The journal also provides the option to include various other types of enhanced features including slide sets, videos and animations. All enhanced features are peer reviewed to the same high standard as the article itself. Peer review is conducted using Editorial Manager®, supported by a database of international experts. This database is shared with other Adis journals.
Manuscripts submitted to the journal for publication will be subject to a $3,000 article processing charge (APC) upon acceptance. Adis Open Access enables you to make your journal article freely available to anyone, in exchange for payment of APC. This option allows you, the author, to retain the copyright of the article according to the terms of the Creative Commons Attribution Non-Commercial (CC BY-NC) License, which does not permit commercial re-use of the article.
- Anton van Rensburg
- Publishing model
- Open Access. Learn about OA at Springer
- 64 days
- Submission to first decision
- 19 days
- Acceptance to publication
- 112,714 (2018)